Here is the design of a clinical trial:

Official Title: A Scalable Solution for Delivery of Diabetes Self-Management Education in Thailand

Included conditions:
- Diabetes Mellitus, Type 2

Study Armgroups:
- {'label': 'DSME program delivered by community health volunteers', 'type': 'ACTIVE_COMPARATOR', 'description': 'Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.', 'interventionNames': ['Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system']}
- {'label': 'DSME program delivered by nurses', 'type': 'ACTIVE_COMPARATOR', 'description': 'Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.', 'interventionNames': ['Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system']}
- {'label': 'Usual care(no DSME program)', 'type': 'NO_INTERVENTION', 'description': 'Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.'}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system', 'description': 'The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.', 'armGroupLabels': ['DSME program delivered by community health volunteers', 'DSME program delivered by nurses']}

Primary Outcomes:
- {'measure': 'Hemoglobin A1c levels (HbA1c)', 'description': 'HbA1c will measures the average blood glucose (sugar) levels months', 'timeFrame': '12 months'}
- {'measure': 'Total cardiovascular risk', 'description': 'The cardiovascular risk will be estimated by Systemic Coronary Risk Evaluation. (SCORE) model. This is a range from 120 to 180 measuring systolic blood pressure (mmHq).', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
An intraclass correlation coefficient of 0.02, a loss-to-follow-up rate of 20%, 80% power, and a 2.5% significance level.
Sample size calculation
        The trial is powered to detect a difference in HbA1c of 0.6% (SD 1.5%) between control and intervention arms, based on the effect size of 0.6% noted in a previous diabetes management study in Thailand,21 and the fact that an increase in HbA1c of ~0.5% was associated with increased mortality among people with diabetes.22 An intraclass correlation coefficient between primary care units of 0.02 was assumed based on a similar study which found that the intraclass correlation for HbA1c at 3âyears was 0.02 (95% CI 0.00 to 0.08).23 Allowing for a loss-to-follow up rate of 20%, 693 participants are needed from 21 primary care units (7 in each trial arm arm) to achieve 80% power at 2.5% significance level.